SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development
Open Access
- 8 February 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (4), 1626
- https://doi.org/10.3390/ijerph18041626
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great threat to public health, being a causative pathogen of a deadly coronavirus disease (COVID-19). It has spread to more than 200 countries and infected millions of individuals globally. Although SARS-CoV-2 has structural/genomic similarities with the previously reported SARS-CoV and MERS-CoV, the specific mutations in its genome make it a novel virus. Available therapeutic strategies failed to control this virus. Despite strict standard operating procedures (SOPs), SARS-CoV-2 has spread globally and it is mutating gradually as well. Diligent efforts, special care, and awareness are needed to reduce transmission among susceptible masses particularly elder people, children, and health care workers. In this review, we highlighted the basic genome organization and structure of SARS-CoV-2. Its transmission dynamics, symptoms, and associated risk factors are discussed. This review also presents the latest mutations identified in its genome, the potential therapeutic options being used, and a brief explanation of vaccine development efforts against COVID-19. The effort will not only help readers to understand the deadly SARS-CoV-2 virus but also provide updated information to researchers for their research work.This publication has 160 references indexed in Scilit:
- d-dimer is a significant prognostic factor in patients with suspected infection and sepsisThe American Journal of Emergency Medicine, 2012
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Rationalizing the development of live attenuated virus vaccinesNature Biotechnology, 2010
- Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus InfectionThe New England Journal of Medicine, 2010
- Coronaviruses post-SARS: update on replication and pathogenesisNature Reviews Microbiology, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirionProceedings of the National Academy of Sciences of the United States of America, 2009
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron CryomicroscopyJournal of Virology, 2006